The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
Open accessAbstract
Importance: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population. Objective: To assess the efficacy and safety of dupilumab monotherapy in adolescents with moderate to severe inadequately controlled AD. Design, Setting, and Participants: A randomized, double-blind, parallel-group, phase 3 clinical trial was conducted at 45 US and Canadian centers between March 21, 2017, and June 5, 2018. A total of 251 adolescents with moderate to severe AD inadequately controlled by topical medications or for whom topical therapy was inadvisable were included. Interventions: Patients were randomized (1:1:1; interactive-response system; stratified by severity and body weight) to 16-week treatment with dupilumab, 200 mg (n = 43; baseline weight <60 kg), or dupilumab, 300 mg (n = 39; baseline weight ≥60 kg), every 2 weeks; dupilumab, 300 mg, every 4 weeks (n = 84); or placebo (n = 85). Main Outcomes and Measures: Proportion of patients with 75% or more improvement from baseline in Eczema Area and Severity Index (EASI-75) (scores range from 0 to 72, with higher scores indicating greater severity) and Investigator's Global Assessment (IGA) 0 or 1 on a 5-point scale (scores range from 0 to 4, with higher scores indicating greater severity) at week 16. Results: A total of 251 patients were randomized (mean [SD] age, 14.5 [1.7] years; 148 [59.0%] male). Of 250 patients with data available on concurrent allergic conditions, most had comorbid type 2 diseases (asthma, 134 [53.6%]; food allergies, 60.8%; allergic rhinitis, 65.6%). A total of 240 patients (95.6%) completed the study. Dupilumab achieved both coprimary end points at week 16. The proportion of patients with EASI-75 improvement from baseline increased (every 2 weeks, 41.5%; every 4 weeks, 38.1%; placebo, 8.2%) with differences vs placebo of 33.2% (95% CI, 21.1%-45.4%) for every 2 weeks and 29.9% (95% CI, 17.9%-41.8%) for every 4 weeks (P < .001). Efficacy of the every-2-week regimen was generally superior to the every-4-week regimen. Patients in the dupilumab arms had higher percentage values of conjunctivitis (every 2 weeks, 9.8%; every 4 weeks, 10.8%; placebo, 4.7%) and injection-site reactions (every 2 weeks, 8.5%; every 4 weeks, 6.0%; placebo, 3.5%), and lower nonherpetic skin infections (every 2 weeks, 9.8%; every 4 weeks, 9.6%; placebo, 18.8%). Conclusions and Relevance: In this study, dupilumab significantly improved AD signs, symptoms, and quality of life in adolescents with moderate to severe AD, with an acceptable safety profile. Placebo-corrected efficacy and safety of dupilumab were similar in adolescents and adults. Trial Registration: ClinicalTrials.gov identifier: NCT03054428.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationBachert, C., Han, J. K., Desrosiers, M., Hellings, P. W., Amin, N., Lee, S. E., Mullol, J., Greos, L. S., Bosso, J. V., Laidlaw, T. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31881-1 · Cited by 1,563
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase Three
Odhiambo, J. A., Williams, H. C., Clayton, T. O., Robertson, C. F., & Asher, M. I. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.009 · Cited by 966
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationEczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health
Shaw, T. E., Currie, G. P., Koudelka, C. W., & Simpson, E. L. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.251 · Cited by 719
Self-citationGuttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Self-citationde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Self-citationEfficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Hirano, I., Dellon, E. S., Hamilton, J. D., Collins, M. H., Peterson, K., Chehade, M., Schoepfer, A. M., Safroneeva, E., Rothenberg, M. E., Falk, G. W., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.042 · Cited by 460
Self-citationMurphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Self-citationPrecise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391
Self-citationIncreasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
Brunner, P. M., Silverberg, J. I., Guttman-Yassky, E., Paller, A. S., Kabashima, K., Amagai, M., Luger, T. A., Deleuran, M., Werfel, T., Eyerich, K., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.022 · Cited by 377
Self-citationSilverberg, J. I., & Simpson, E. L. (2013) · Pediatric Allergy and Immunology · doi:10.1111/pai.12095 · Cited by 310
Self-citationMajor Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders
Paller, A., Jaworski, J. C., Simpson, E. L., Boguniewicz, M., Russell, J. J., Block, J. K., Tofte, S., Dunn, J. D., Feldman, S. R., Clark, A. R., et al. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0383-4 · Cited by 274
Self-citationBrunner, P. M., Suárez-Fariñas, M., He, H., Malik, K., Wen, H.-C., Gonzalez, J., Chan, T. C.-C., Estrada, Y., Zheng, X., Khattri, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09207-z · Cited by 260
Self-citationAn Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., Correa da Rosa, J., Shemer, A., Krueger, J. G., Suarez-Farinas, M., & Guttman-Yassky, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.037 · Cited by 213
Self-citationDupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
Corren, J., Castro, M., O'Riordan, T., Hanania, N. A., Pavord, I. D., Quirce, S., Chipps, B. E., Wenzel, S. E., Thangavelu, K., Rice, M. S., et al. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.08.050 · Cited by 203
Self-citationDrucker, A. M., Eyerich, K., de Bruin-Weller, M. S., Thyssen, J. P., Spuls, P. I., Irvine, A. D., Girolomoni, G., Dhar, S., Flohr, C., Murrell, D. F., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.15928 · Cited by 184
Self-citationDepression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis
Slattery, M. J., Essex, M. J., Paletz, E. M., Vanness, E. R., Infante, M., Rogers, G. M., & Gern, J. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.003 · Cited by 159
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Hultsch, T., Davis, J. D., Zhang, Y., Zhu, X., Chen, Z., Li, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18476 · Cited by 154
Self-citationHalvorsen, J. A., Lien, L., Dalgard, F. J., Bjertness, E., & Stern, R. S. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.70 · Cited by 115
Totri, C. R., Eichenfield, L. F., Logan, K., Proudfoot, L. E., Schmitt, J. M., Lara‐Corrales, I., Sugarman, J., Tom, W. L., Siegfried, E. C., Cordoro, K. M., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.021 · Cited by 90
Self-citationShrestha, S., Miao, R., Wang, L., Chao, J., Yüce, H., & Wei, W. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0582-z · Cited by 86
Quality of Life of Parents of Children with Atopic Dermatitis
Marciniak, J., Reich, A., & Szepietowski, J. C. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2633 · Cited by 82
Kou, K., Aihara, M., Matsunaga, T., Chen, H., Taguri, M., Morita, S., Fujita, H., Yamaguchi, Y., Kambara, T., & Ikezawa, Z. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1198-9 · Cited by 77
Current and Future Biomarkers in Atopic Dermatitis
Thijs, J. L., de Bruin-Weller, M. S., & Hijnen, D. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.008 · Cited by 49
Atopic dermatitis in adolescence
Ricci, G., Bellini, F., Dondi, A., Patrizi, A., & Pession, A. (2011) · Dermatology Reports · doi:10.4081/dr.2012.e1 · Cited by 46
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.054 · Cited by 399
Self-citationJAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Self-citationPaller, A. S., Simpson, E. L., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Soong, W., Gonzalez, M. E., Schneider, L. C., Sidbury, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01539-2 · Cited by 281
Self-citationRenert-Yuval, Y., Del Duca, E., Pavel, A. B., Fang, M., Lefferdink, R., Wu, J., Diaz, A., Estrada, Y. D., Canter, T., Zhang, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.001 · Cited by 168
Self-citation
Metadata
- Authors
- Simpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M. J., Beck, L. A., Guttman-Yassky, E., Pariser, D., Blauvelt, A., Weisman, J., Lockshin, B., Hultsch, T., Zhang, Q., Kamal, M. A., Davis, J. D., Akinlade, B., Staudinger, H., Hamilton, J. D., Graham, N. M. H., Pirozzi, G., Gadkari, A., Eckert, L., Stahl, N., Yancopoulos, G. D., Ruddy, M., & Bansal, A.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-01-01
- Volume
- 156
- Issue
- 1
- Pages
- 44
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2988092601
- Cited by
- 524
- References
- 37
- FWCI
- 46.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.